5/2/2013

France is now requiring that its health care authority review real-world data about pricing decisions for reimbursed drugs and devices, and that companies conduct stringent post-reimbursement studies to determine price-control levels. At present, the government uses cost-benefits studies by the country's independent health authority to set prices for reimbursed products. The government is also seeking to cut prices for generics by even greater amounts than previously through a "reference price" mechanism.

Full Story:
Clinica

Related Summaries